New products of interest to our readers
FDA approves garadacimab-gxii to prevent HAE attacks in patients aged 12 years, older
Garadacimab-gxii is the only treatment to target factor Xlla for prophylactic use to prevent attacks of HAE in patients aged 12 years and older.
Food Insecurity and the Dangers of Infant Formula Dilution
FDA approves new presentation of ustekinumab-stba biosimilar for plaque psoriasis, psoriatic arthritis
The approval for ustekinumab-stba now offers all dosage forms to the reference product, ustekinumab, and is indicated for patients aged 6 to 17 years.
Demystifying Infant Formula
Weekly review: Clesrovimab for RSV approved, new dupilumab data, and more
Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.
Yale researchers identify new biomarker panel to assess risk of chronic kidney disease progression in children
